Background: Right heart catheterisation (RHC) is an important test for the diagnosis and subclassification of pulmonary hypertension (PH), one of the serious manifestations of systemic sclerosis (SSc). It provides haemodynamic information for diagnosis and management. Routine RHC in SSc cases with suspected PH permits blood sampling to explore plasma levels of key cytokines that may be markers of mediators of pulmonary arterial hypertension (PAH) pathogenesis. Objectives: This is an exploratory study to assess for associations between plasma cytokine levels and haemodynamic assessment from RHC in SSc patients. Methods: SSc patients undergoing routine RHC were recruited. Indications for referral included suspected PH, or those on treatment for established PH for assessment of response to therapy. Blood samples were collected during RHC in consented patients. Demographic and clinical data were obtained. Haemodynamic data from RHC including mean right atrial pressure (mRAP), mean pulmonary arterial pressure (mPAP), pulmonary capillary wedge pressure (PCWP), pulmonary vascular resistance (PVR), cardiac output (CO) and cardiac index (CI) were recorded. Plasma samples were analysed using a bead-based multiplex platform for IL1b, IL4, IL6, IL10, IL17A, IL17F, IL21, IL22, IL23, IL25,  IL31 , IL33, IFNg, sCD40L and TNFa (Bio-Rad Pro Assays). Plasma from a small group of healthy controls were also analysed for comparison. For analytes found to be below the lower limit of detection of the assays, they were assumed to be equal to the lower limit of the detection as per the assay's protocol. Results: 32 SSc patients were recruited. Their mean age was 59.4-year-old, and 31 of them (97%) were female. Most (n=29, 91%) had limited cutaneous SSc. The commonest antibody was anti-centromere antibody (n=16, 55%), followed by anti-U3RNP antibody (n=4, 14%). None of these patients had significant pulmonary fibrosis (≥20% involvement on HRCT thorax scan). PAH, defined as mPAP ≥25mmHg & PCWP ≤15mmHg, was diagnosed at RHC in 26 patients (81%). Among the proteins tested, only the level of sCD40L was significantly different among the three groups, namely SSc with PH, SSc without PH and healthy controls (p=0.008). sCD40L was also the only biomarker which was significant higher among patients with SSc (with and without PH) than healthy controls (p=0.0284). Interestingly, there was a weak negative correlation between sCD40L and mPAP (correlation coefficient=-0.35, p=0.0486). There was a moderately strong positive correlation between mRAP and IL4 (correlation coefficient=0.57, p=0.0006) and IL10 (correlation coefficient=0.51, p=0.0028). We found no evidence for association between any of the biomarkers and cardiac output, cardiac index, PCWP or PVR. Conclusions: Our data suggest that some individual plasma proteins may correlate with specific RHC haemodynamic parameters. Future studies will extend these findings and explore whether combining multiple analytes may give stronger non-invasive prediction of relevant haemodynamic variables and could be used in detection or monitoring of PAH in SSc. Background: The enzymes IDO degrades Trp into Kyn and is induced by IFN-gamma/IL-1. Neo is produced by monocytes/macrophages after IFN-gamma stimulation through the enzyme GTPCH and is a biomarker for monitoring immune activation in several diseases [1] . The activity of GTPCH is induced in parallel to IDO and the Kyn/Trp ratio has been suggested to be a direct measure of IDO activity [2] . Objectives: To assess serum level of Kyn, Trp, Neo and Kyn/Trp ratio in SSc and potential associations with specific disease features. Methods: 60 SSc pts and 10 healthy controls (HC) were recruited and serum levels of Kyn, Trp and Neo were measured. Kyn/Trp ratio was calculated. The results were then correlated with specific disease features: disease duration, limited or diffuse disease, autoantibody profile (anti-RNA pol III (ARA), antitopoisomerase (ATA) and anti-centromere (ACA)), inflammatory markers, Hb level, concurrent modified Rodnan skin score (mRSS), peak mRSS, pulmonary fibrosis (PF), pulmonary arterial hypertension (PAH), history of scleroderma renal crisis (SRC), GI involvement, vasculopathy, environmental exposure, oncology history, smoking status, immunosuppressive treatment, NT-proBNP and urate levels. Non-parametric statistical tests were used. Results: Kyn/Trp ratio was higher in SSc compared to HC (mean 49.97±32.77 [41.50 -58.43 Malnutrition was defined accordingly to recently published and widely accepted ESPEN criteria (1); sarcopenia was diagnosed in patients with a reduced skeletal muscle index (2). Results: The table summarizes cohort's characteristics. Malnutrition was diagnosed in 9.2% (CI95%: 4.4-14.0%). Malnourished patients were more often treated with steroids (p=0.039), had worse gastrointestinal symptoms accordingly to UCLA questionnaire (p=0.007), lower physical activity accordingly to International physical activity questionnaire (p=0.028), longer disease duration (p=0.019), worse predicted DLCO/VA and FVC (p=0.009, respectively) and worse disease severity accordingly to Medsger severity score (DSS) (p<0.001 for total, p=0.001 for lung and p<0.001 for gastrointestinal tract). In multivariate analysis only FVC (p=0.006) and disease severity (p=0.003), in particular lung involvement as defined by DSS (p=0.013), were confirmed to be worse in malnourished patients. Z-scores were significantly lower in malnourished patients at lumbar site p=0.033), even after correcting for possible confounders. Sarcopenia was diagnosed in 20.7% (CI95% 14.0-27.4%); 11/29 sarcopenic patients were also malnourished and 6/29 were cachectic (i.e. sarcopenia + systemic inflammation). Sarcopenic patients had worse DLCO/VA (p=0.003) and lung (p=0.005) involvement accordingly to DSS than non-sarcopenic ones; cachectic had even lower value (p=0.016 for both). Sarcopenic patients had also longer disease duration (p=0.033). Conclusions: Malnutrition defined with widely accepted diagnostic criteria was found to be lower than previously reported (3-7) using screening tool or nonvalidated criteria. Sarcopenia was found to be somewhat common, although no previous study on comparable cohorts are available. Lung involvement and function was shown to be significantly linked with nutritional status and may not be explained only by muscle weakness given the absence of correlation between muscle weakness and FVC but only with DLCO/VA. To analyse the association between organ involvement and PROs in IIM patients, taking the presence of autoantibodies into account. Methods: Data of IIM patients, recorded in the National Database of the German collaborative arthritis centres between 2007 and 2014, were analysed. Physicianreported data on myositis disease phenotypes, organ involvement and antibody status were linked with PROs on functional status (FFbH, range 0-100, 100 indicating full capability), and numerical rating scales (0-10) for pain, fatigue, general health, physical and emotional well-being and coping. Multivariable linear regression analysis was used to investigate the impact of phenotype, organ involvement and autoantibodies on PROs, adjusted for sex, age and disease duration. Results: A total of 142 IIM patients -60 polymyositis (PM), 46 dermatomyositis (DM), 15 antisynthetase syndrome (ASS), 12 overlap (OL), 9 others -with mean disease duration of 7.4 years were included. 85% showed muscular, 36% skin involvement, 22% arthritis, 28% interstitial lung disease, 17% dysphagia and 9% cardiomyopathy. Visceral (lung, cardiac or gastrointestinal) manifestation was present in 46% (PM), 54% (DM), 100% (ASS), and 80% (overlap). While moderate to severe (4-10) fatigue was predominately reported in overlap (64%) and ASS (70%), pain was more frequent in overlap (55%) and emotional discomfort was reported most frequently in ASS (57%). For all PROs, worse outcomes were documented in patients with visceral manifestation. Myositisspecific autoantibodies, predominantly Anti-Jo1, were present in 63% of the patients, and were associated with more frequent visceral manifestation (73% vs. 46%), especially interstitial lung disease (50% vs. 15%), and arthritis (32% vs. 13%), but less skin involvement (26% vs. 49%). DM and PM subtypes showed almost identical coefficients for fatigue, physical well-being, general health and coping, while PM was associated with higher emotional strain. Pulmonary hypertension had a severe impact on pain, functional status and daily activities. Cardiomyopathy was associated with impaired general health, arthritis with poorer scores for coping, physical and emotional well-being. Conclusions: IIM patients with distinct subtypes differ considerably regarding the frequency of organ involvement and self-reported dimensions of disease burden. Anti-Jo1 positivity is associated with higher visceral organ involvement and arthritic manifestations and may therefore also indicate a higher patient-reported disease burden. 
